Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (HFrEF)
Dr. Kenneth Freedberg was standing at his wife’s bedside in a Boston hospital’s intensive care unit when an unexpected visitor entered: Dr. Rochelle Walensky.
“We were there for no more than 45 minutes when Rochelle walks in,” said Freedberg, a professor of medicine at Harvard Medical School.
“She didn’t work there,” he said, recalling his friend Walensky’s visit after his wife had suddenly taken ill 10 years ago. “She is always there for people she is committed to, and she is committed to a lot of people.”
As the newly-appointed director of the Centers for Disease Control and Prevention (CDC), Walensky’s list of commitments has grown exponentially, a task friends and family of the Newton, Massachusetts resident agree she is uniquely prepared to handle.
National
February 6, 2021
LAHORE: Global funding for COVID-19 vaccine development has exceeded 10 times in less than a year the amount allocated for HIV and TB research and development in 11 years.
“A staggering amount of $103.8 billion has been thrust into COVID-19 vaccine development within a period of just 11 months of 2020 as compared to a paltry $9.5 billion ($8.5 billion for HIV and $1billion for TB) for HIV and TB research and vaccine development during 11-year period from 2009 to 2019,” according to the statistical data compiled by Treatment Action Group (TAG-USA).
“According to KENUP Foundation, the governments, to-date, spent at least $111.6 billion on COVID-19 vaccines and therapeutics, 95 per cent of which went into coronavirus vaccine development alone. It betrays a whopping amount of $103.8 billion spent on COVID19 vaccine research and development alone,” says Mike Frick from TAG-USA quoting the latest statistics on R&D funding at a session titled “HIV &
ECMO life-support therapy can increase odds of survival for critically-ill COVID-19 patients
COVID-19 has caused more than 2 million deaths worldwide since the World Health Organization declared it a pandemic in March 2020. Patients with severe COVID-19 frequently experience respiratory distress and require assistance breathing. For patients whose lungs are so injured that even a ventilator is unable to deliver enough oxygen, extracorporeal membrane oxygenation (ECMO) which does the work of the lungs by removing carbon dioxide and adding oxygen to blood outside the body may improve the odds of survival for certain patients with severe COVID-19.
A study by physician-researchers at Beth Israel Deaconess Medical Center (BIDMC) and Brigham and Women s Hospital (BWH) provides new evidence that critically ill patients with COVID-19 who were treated with ECMO had better odds of survival than those who were not treated with ECMO. The findings published in
Date Time
Share
New evidence sheds light on best practices for treating patients with severe respiratory failure from COVID-19
Findings suggest ECMO life-support therapy can improve odds of survival for patients critically ill with COVID-19
BOSTON – COVID-19 has caused more than 2 million deaths worldwide since the World Health Organization declared it a pandemic in March 2020. Patients with severe COVID-19 frequently experience respiratory distress and require assistance breathing. For patients whose lungs are so injured that even a ventilator is unable to deliver enough oxygen, extracorporeal membrane oxygenation (ECMO) which does the work of the lungs by removing carbon dioxide and adding oxygen to blood outside the body may improve the odds of survival for certain patients with severe COVID-19.